Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25751714 | 0.91 | P2RY12 (0.39) | P2RY12ADORA1 | |
| SCHEMBL20621652 | 0.87 | P2RY12 (0.46) | P2RY12P2RY2 | |
| SCHEMBL25752506 | 0.86 | P2RY12 (0.35) | P2RY12 | |
| SCHEMBL25751704 | 0.80 | P2RY12 (0.47) | P2RY12P2RY2 | |
| SCHEMBL25751720 | 0.79 | RXFP1 (0.34) | P2RY12ADORA1 | |
| SCHEMBL30546917 | 0.75 | RXFP1 (0.40) | P2RY12P2RY2 | |
| SCHEMBL25751718 | 0.75 | P2RY12 (0.39) | P2RY12 | |
| SCHEMBL30546907 | 0.75 | RXFP1 (0.42) | P2RY12ADORA1 | |
| SCHEMBL31572053 | 0.72 | P2RY12 (0.44) | P2RY12 | |
| SCHEMBL20603094 | 0.72 | P2RY12 (0.44) | P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | HAVCR2, CD4, CCR1 | P2RY12 2789/4885ADORA1 2149/4885P2RY2 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.